Company Overview
Profound Medical Corp. operates as a commercial-stage medical device company focused on developing and marketing AI-powered, MRI-guided, incision-free therapeutic systems designed for the image-guided ablation of diseased tissue. This business model places the firm within the healthcare sector, specifically the medical devices industry, where innovation in therapeutic imaging and treatment delivery is critical for advancing patient care standards. The company currently maintains a market capitalization of $211.23M and employs a workforce of 162 individuals to support its product development and commercialization efforts. While the annual revenue stands at $16.10M, the market cap indicates a valuation that significantly exceeds current sales figures, suggesting the market places a high premium on the company's future growth potential and intellectual property rather than its current cash generation.
Financial Health
The company reported revenue of $16.10M over the trailing twelve months, yet it recorded a net income of -$42,570,000 and an EBITDA of -$40,694,000. The substantial gap between the $16.10M revenue and the -$42,570,000 net income reveals a cost structure where operating expenses and losses far outweigh the gross revenue generated from sales. Free cash flow for the period was -$20,897,750, indicating that the company is currently burning cash, which limits immediate financial flexibility but may be necessary for funding research and development in the early commercial stages. Gross margin stands at 70.8%, reflecting high pricing power or low cost of goods sold relative to sales, while the operating margin is -123.3% and the profit margin is -264.4%, signaling significant operational inefficiencies or heavy investment in expenses that depress profitability at the current scale. The company holds $59.72M in cash against $4.71M in debt, resulting in a debt-to-equity ratio of 7.09, which suggests a highly leveraged balance sheet relative to equity, although the substantial cash reserve provides a buffer against short-term obligations. The current ratio is 12.53, a figure that indicates exceptionally strong short-term liquidity and the ability to cover current liabilities more than twelve times over. Return on Equity is -67.1% and Return on Assets is -34.9%, metrics that reveal that management is currently generating negative returns on the capital invested by shareholders and held in assets, likely due to the heavy upfront costs associated with bringing a new medical device to market.
Valuation Assessment
The trailing P/E ratio is N/A due to negative earnings, while the forward P/E is -7.42, a disparity that implies the market is pricing in a turnaround or expects earnings to become positive in the future, though the negative forward multiple itself reflects current expectations of continued losses. The price-to-book ratio is 3.18, indicating that the stock trades at a significant premium over its book value, which suggests investors are paying for future growth expectations rather than current asset backing. Alternative valuation metrics such as the price-to-sales ratio of 13.12 and an EV/EBITDA of -3.84 further illustrate that the company is valued heavily on its sales base despite negative earnings, a common characteristic of pre-profitability growth-stage companies. The stock has traded between a 52-week low of $3.76 and a 52-week high of $8.95, and the current valuation context must be viewed against this range where the price has demonstrated significant volatility. The beta value is 0.39, which indicates that the stock's price volatility is substantially lower than that of the broader market, suggesting it may be less sensitive to general market fluctuations.
Growth & Income
Revenue growth year-over-year is 43.1%, while earnings growth is N/A due to the company's net loss position, meaning earnings are not growing in the traditional sense but rather moving from a loss toward profitability as the business scales. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, indicating that the firm reinvests all available resources and retained earnings into growth initiatives rather than distributing income to shareholders. The absence of a dividend yield reflects a strategy typical for companies in the commercial-stage that prioritize capital allocation toward expanding their therapeutic systems and market penetration over providing immediate cash returns to investors. Overall, the growth and income profile is characterized by rapid top-line expansion paired with significant cash burn and no current income distribution, positioning the company as a high-risk, high-potential equity in the medical device sector.